12.01.07
Metagenics, Inc., San Clemente, CA, has been awarded three new patents for discoveries relating to Luduxin and Tetrase, two all-natural selective kinase response modifier (SKRM) formulations with powerful anti-inflammatory properties. U.S. Patent No. 7,270,835 protects the composition of Luduxin, a proprietary formula consisting of rho iso-alpha acids (RIAA) derived from hops, as well as the use of Luduxin in preserving joint health. U.S. Patent No. 7,195,785 and 7,205,151 protect the composition of Tetrase, a proprietary formula comprising of tetrahydro-isohumulone, a tetrahydro iso-alpha acid derived from hops, as well the use of Tetrase to support the management of inflammation.